Neoplasms, Unknown Primary: Clinical Trials

4 terminated. 4 Phase 2, 2 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	4	Terminated 4
Phase 1	2	Terminated 2

Follow Neoplasms, Unknown Primary: new trials by email Literature Review of Neoplasms, Unknown Primary trials Research Report on Neoplasms, Unknown Primary

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin. ReposMBZ - Cancer of the Gastrointestinal Tract, Cancer of Unknown Origin	Phase 1 / Phase 2	Terminated	Repos Pharma	11	2018-05-25	2020-01-22
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary Capecitabine, Carboplatin, Paclitaxel - Tumors, Unknown Primary Tumors	Phase 1 / Phase 2	Terminated	Ohio State University Comprehensive Cancer Center	57	2005-06-01	2016-09-23
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site Carboplatin, Gemcitabine, Capecitabine - Carcinoma of Unknown Primary	Phase 2	Terminated	University of Michigan Rogel Cancer Center		2001-05-01	2008-01-10
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin Antineoplaston therapy (Atengenal + Astugenal) - Unknown Primary Carcinoma	Phase 2	Terminated	Burzynski Research Institute	8	1996-03-18	2020-12-17

Narrower conditions

Adenocarcinoma (1)  ·  Gastrointestinal Neoplasms (1)  ·  Neoplasms (1)

Broader conditions

Neoplasm Metastasis (4)  ·  Neoplastic Processes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Neoplasms (3)  ·  Carcinoma (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Glandular and Epithelial (1)

Interventions

Capecitabine (2)  ·  Carboplatin (2)  ·  Gemcitabine (1)  ·  Mebendazole (1)  ·  Paclitaxel (1)  ·  antineoplaston A10 (1)  ·  antineoplaston AS 2-1 (1)

Sponsors

Burzynski Research Institute (1)  ·  Ohio State University Comprehensive Cancer Center (1)  ·  Repos Pharma (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (3)  ·  Sweden (1)

Top investigators

Mark Zalupski, M.D. (1)  ·  Stanislaw R. Burzynski, MD, PhD (1)  ·  Tony Bekaii-Saab (1)